The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.
A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.
American Society of Clinical Oncology presentations show the unmet need for methods to predict autoimmune toxicities in checkpoint blockade-treated individuals.
The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.
The study will use OncoDNA's liquid biopsy tech to profile and identify treatment options for 100 patients in Lebanon, Jordan, Saudi Arabia, and the UAE.
The approach, dubbed ThromboSeq, enables clinical researchers to identify different cancer types by looking at tumor-educated, platelet-derived RNA using RNA-seq.
Researchers found that telomeres were shorter in tumors than in normal tissues and longer in sarcomas and gliomas than in other cancers.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
The company said it will use the proceeds of the financing to continue the development of a technology platform and associated applications.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.